Literature DB >> 27189148

Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.

Lawrence Kashat1, Steven Orlov1, David Orlov1, Jasmeet Assi1, Farnaz Salari1, Paul G Walfish2,3.   

Abstract

The purpose of this study was to determine the natural temporal trends of serial thyroglobulin (Tg) among low/intermediate-risk PTC patients not receiving radioactive iodine (RAI) using TSH-stimulated Tg (Stim-Tg) and unstimulated highly sensitive Tg (u-hsTg). We prospectively analyzed serial Stim-Tg measurements after total thyroidectomy ± therapeutic central neck dissection among 121 consecutive low/intermediate-risk PTC patients who did not receive RAI, of whom 104 also had serial u-hsTg measurements available. Median follow-up was 6.5 years with Stim-Tg measurements commencing 3 months after surgery and u-hsTg commencing 1.8 years after surgery (when the assay became available). TSH stimulation was performed with 9-day T3 withdrawal, 22-day T4 withdrawal, or using recombinant human TSH (rhTSH). To account for within-patient correlations of repeated Tg measurements, temporal trends in Stim-Tg and u-hsTg were assessed using Generalized Estimating Equations. Stim-Tg models were adjusted for the method of TSH stimulation, whereas the u-hsTg models were adjusted for concurrent TSH level. Linear regression modeling was used to assess the trend in serial Stim-Tg and u-hsTg measurements as a function time from time of surgery throughout the duration of follow-up. The main outcome measured was the change in u-hsTg and Stim-Tg measurements over time. A total of 337 Stim-Tg (2.8/patient) and 602 u-hsTg (5.8/patient) measurements were analyzed. Among the 337 Stim-Tg measurements, Stim-Tg was assessed using rhTSH in 202 (60 %), T4 withdrawal in 41 (12 %), and T3 withdrawal in 94 (28 %) measurements. The overall mean ± 1SD for Stim-Tg and u-hsTg measured was 1.0 ± 1.2 and 0.2 ± 0.1 μg/L, respectively. When adjusted for method of TSH stimulation, serial Stim-Tg measurements did not significantly change over time (all p = NS). The estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were 0.01, -0.08, and 0.04 μg/L, respectively. Upon exclusion of 73 patients with an initial undetectable Stim-Tg (n = 48), serial Stim-Tg measurements did not change significantly over time (all p = NS). For these patients, the estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were -0.09, -0.10, and 0.01 μg/L, respectively. Serial u-hsTg measurements did not significantly change over time after adjusting for TSH level (p = NS). The estimated change in u-hsTg per year was -0.003 μg/L. No patients had any clinical or imaging evidence of a recurrence during the duration of their follow-up. Among low/intermediate-risk PTC patients not treated with RAI, serial post-surgical Stim-Tg and u-hsTg measurements do not change significantly over a median follow-up of 6.5 years.

Entities:  

Keywords:  Papillary thyroid cancer; Post-surgical; Stimulated thyroglobulin; Thyroglobulin; Unstimulated highly sensitive thyroglobulin

Mesh:

Substances:

Year:  2016        PMID: 27189148     DOI: 10.1007/s12020-016-0989-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  18 in total

1.  Use of recombinant thyrotropin.

Authors:  Anthony Toft; Geoffrey Beckett
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference.

Authors:  Alicia Algeciras-Schimnich; Michael A Lasho; Karl M Ness; Lynn A Cheryk; Stefan K G Grebe
Journal:  Thyroid       Date:  2011-07       Impact factor: 6.568

4.  To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health.

Authors:  Alan E Hubbard; Jennifer Ahern; Nancy L Fleischer; Mark Van der Laan; Sheri A Lippman; Nicholas Jewell; Tim Bruckner; William A Satariano
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

5.  Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.

Authors:  Alon Vaisman; Steven Orlov; Jonathan Yip; Cindy Hu; Terence Lim; Mark Dowar; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2010-06       Impact factor: 3.147

6.  Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.

Authors:  Rosália P Padovani; Eyal Robenshtok; Matvey Brokhin; R Michael Tuttle
Journal:  Thyroid       Date:  2012-07-10       Impact factor: 6.568

7.  Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?

Authors:  Cosimo Durante; Teresa Montesano; Marco Attard; Massimo Torlontano; Fabio Monzani; Giuseppe Costante; Domenico Meringolo; Marco Ferdeghini; Salvatore Tumino; Livia Lamartina; Alessandra Paciaroni; Michela Massa; Laura Giacomelli; Giuseppe Ronga; Sebastiano Filetti
Journal:  J Clin Endocrinol Metab       Date:  2012-06-07       Impact factor: 5.958

8.  Serum Thyroglobulin Measured With a Second-Generation Assay in Patients Undergoing Total Thyroidectomy Without Radioiodine Remnant Ablation: A Prospective Study.

Authors:  Pedro Weslley Rosario; Gabriela Franco Mourão; Thássio Leonardo Siman; Maria Regina Calsolari
Journal:  Thyroid       Date:  2015-04-13       Impact factor: 6.568

9.  Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma.

Authors:  Steven Orlov; David Orlov; Michael Shaytzag; Mark Dowar; Vafa Tabatabaie; Philip Dwek; Jonathan Yip; Cindy Hu; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2009-06       Impact factor: 3.147

10.  Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.

Authors:  C Nascimento; I Borget; F Troalen; A Al Ghuzlan; D Deandreis; D Hartl; J Lumbroso; C N Chougnet; E Baudin; M Schlumberger; S Leboulleux
Journal:  Eur J Endocrinol       Date:  2013-10-04       Impact factor: 6.664

View more
  4 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

2.  Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?

Authors:  Maria F Bates; Marcos R Lamas; Reese W Randle; Kristin L Long; Susan C Pitt; David F Schneider; Rebecca S Sippel
Journal:  Surgery       Date:  2017-11-08       Impact factor: 3.982

3.  Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.

Authors:  Fernanda Bueno; María Gabriela García Falcone; Mirna Angela Peñaloza; Erika Abelleira; Fabián Pitoia
Journal:  Endocrine       Date:  2019-10-24       Impact factor: 3.633

Review 4.  Strategies for Radioiodine Treatment: What's New.

Authors:  Clotilde Sparano; Sophie Moog; Julien Hadoux; Corinne Dupuy; Abir Al Ghuzlan; Ingrid Breuskin; Joanne Guerlain; Dana Hartl; Eric Baudin; Livia Lamartina
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.